Experts in TLR Biology

We are developing cutting edge immunotherapies based on Toll-Like Receptor (TLR) biology and its ability to modulate the immune system. Learn More >

Cancer Immunotherapy

Through our expertise in TLR biology we have designed compounds that stimulate multiple innate mechanisms of tumor killing and development of immune memory associated with tumor-specific antigens. Learn More >

‹ ›

HEPLISAV-B™

HEPLISAV-B is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary TLR9 agonist to enhance the immune response. HEPLISAV-B is currently in Phase 3 clinical trials.

Learn More ›

Toll-like Receptor (TLR) Platform

Our TLR platform is broadly applicable across multiple diseases including infectious diseases, cancer and asthma.

Learn More ›

News

Mar02

Dynavax Announces Second Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM)

Feb27

Dynavax to Present at the Cowen and Company 35th Annual Health Care Conference

Feb19

Dynavax to Present at the 2015 RBC Capital Markets' Global Healthcare Conference

View All News

Our values

At Dynavax we are proud of work we do. Our corporate values provide the foundation of our culture and how we operate as a company.

Learn More ›